Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors

Journal of Neuro-Oncology

Volumn 108, Issue 3, 2012, Pages 361-373

  Takano, Shingo ^a   Kato, Yukinari ^b   Yamamoto, Tetsuya ^a   Kaneko, Mika Kato ^b   Ishikawa, Eiichi ^a   Tsujimoto, Yuta ^b   Matsuda, Masahide ^a   Nakai, Kei ^a   Yanagiya, Ryo ^b   Morita, Shunpei ^b   Tsuboi, Koji ^a   Matsumura, Akira ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

Glioma; IDH1; Immunohistochemistry; Internexin; Monoclonal antibody; Mutation; P53

Indexed keywords

INTERNEXIN; ISOCITRATE DEHYDROGENASE 1; MEMBRANE PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY; NIMUSTINE; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOMA; HUMANS; IMMUNIZATION; IMMUNOENZYME TECHNIQUES; INTERMEDIATE FILAMENT PROTEINS; ISOCITRATE DEHYDROGENASE; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PEPTIDE FRAGMENTS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84864030931     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0837-0     Document Type: Article

References (39)

1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
2. Sonoda Y, Kumabe T, Nakamura T, Kanamori M, Yamashita Y, Suzuki H, Tominaga T (2009) Analysis of IDH1 and IDH2 muta-tions in Japanese glioma patients. Cancer Sci 100:1996-1998
3. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149-1153
4. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Drig-gers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744
5. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1β. Science 324:261-265
6. Williams SC, Karajannis MA, Chiriboga L, Golfin JG, von Deimling A, Zagzag D (2011) R132H mutantion of isocitrate dehydrogenase-1 is not efficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 121:274-281
7. Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, de Paula AM, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot O, Ouafik LH, Figarella-Branger D (2011) IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol 105(3):591-600
8. R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547-551
9. Kaneko M, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K Yamazaki K, Kitanaka C, Kato Y (2011) Establishment of a novel monoclonal antibody SMab-1 specific for IDH1 R132S mutation. Biochem Biophys Res Commun 406:608-613
10. Capper D, Zentqraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599-601
11. Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Yamazaki K, Kato Y, Matsumura A (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochem-istry and sequencing. Brain Tumor Pathol 28:115-123
12. Ducray F, Criniere E, Idbaih A, Mokhtari K, Maric Y, Paris S, Navarro S, Laigle-Donadey F, Dehais C, Thilet J, Hoang-Xuan K, Delattre JY, Sanson M (2009) Alpha-internexin expression identifies 1p19q codeleted gliomas. Neurology 72:156-161
13. Ducray F, Mokhtari K, Crinière E, Idbaih A, Marie Y, Dehais C, Paris S, Carpentier C, Dieme MJ, Adam C, Hoang-Xuan K, Duyckaerts C, Delattre JY, Sanson M (2011) Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 47:802-808
14. Durand K, Guillaudeau A, Pommepuy I, Mesturoux L, Chaunavel A, Gadeaud E, Porcheron M, Moreau JJ, Labrousse F (2011) Alpha-internexin in gliomas, relationship with histo-logical type and 1p, 19q, 10p and 10q status. J Clin Pathol 64:793-801
15. Mokhtari K, Ducray F, Kros JM, Gorlia T, Idbaih A, Taphoom M, Wesseling P, Hoang-Xuan K, van den Bent M, sanson M (2011) Alpha-internexin expression predicts outcome IN ana-plastic oligodendroglial tumors and may positively impact the efficacy ofchemotherapy. Cancer 117:3014-3026
16. Preusser M, Wohrer A, Stary S, Hoftberger R, Streubel B, Hainfellner JA (2011) Value and limitations of immunohisto-chemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 70:715-723
17. Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T (2010) O6-Methylguanine DNA methyltransferase determined by promoter hypermethyla-tion and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15:352-358
18. Christman M, Naegel G, Hom S, Krhan U, Wiewroft D, Sommer C, Kaima B (2010) MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer 127:2106-2118
19. Momota H, narita Y, Matsushita Y, Miyakita Y, Shibui S (2010) p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol 27:95-101
20. Pardo FS, Hsu DW, Zeheb R, Efird JT, Okurief PG, Malkin DM (2004) Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Br J Cancer 91:1678-1686 (Pubitemid 39546141)
21. Kloosterhof NK, Bralte LB, Dubbink HJ, French PJ, van den Bent M (2011) Isocitrate dehydrogenase-1 mutations: a funda-mentally new understanding of diffuse glioma? Lancet Oncol 12:83-91
22. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisseller B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
23. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoom MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group. Clin Cancer Res 16:1597-1604
24. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reif-energer G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707-718
25. Gupta R, Webb-Myers R, Flanagan S, Buckland ME (2011) Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 64:835-844 (July 12 [Epub ahead of print])
26. Capper D, Weibert S, Balss J, Habel A, Meyer J, Jager D, Ac-kermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254
27. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ (2009) IDH1 mutations in astrocytomas predict survival but not response to temozolomide. Neurology 73:1792-1795
28. Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW (2011) IDH1 mutations in grade II astro-cytomas are associated with unfavorable progression-free sur-vival and prolonged postrecurrence survival. Cancer 118(2): 452-460
29. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawaski R, Watanabe T, de Girolami U, Kleihues P, Ohgaki H (2010) Molecular classification of low-grade diffuse glioma. Am J Pathol 177:2708-2714
30. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guilevin R, Laffaire J, Paris S, Boisselier B, Idbah A, Laigle-Donadey F, Sanson M, Delattre JY (2010) IDH1 or IDH2 mutations predict longer survival and response to temozlomide in low-grade glio-mas. Neurology 75:1560-1566
31. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB, European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group, European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-2084 (Pubitemid 34408798)
32. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhatari K, Wang XW, Lo-undou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiological and molecular subtype of WHO grade II gliomas with dismal prognosis. ActaNeuropathol 120:719-729
33. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5-12 (Pubitemid 24074995)
34. Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathway in the evolution of gliomas. Cancer Sci 100:2235-2241
35. Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M (2011) Expression ofmutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. Folia Neuropathol 49:88-93
36. Kurtkaya-Yapicier O, Scheithauer BW, Hebrink D, James CD (2002) p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study. Neurosur-gery 51:1246-1254
37. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss dis-tinguish oligodendrogliomas from other cancers. J Pathol 226(1):7-16
38. Precusser M, Charles JR, Felsberg J, Reifenberger G, Hanou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heizl H, Hainfellner JA, Hegi M (2008) Anti-O6-methylguanine-methytransferase (MGMT) immunohistochemistry in glioblastoma multiforme observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520-532
39. Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastoma. Neurosurgery 65:866-875